Choosing a first-line drug in the management of elevated blood pressure: what is the evidence? 1: Thiazide diuretics.
- 11 July 2000
- journal article
- review article
- Vol. 163 (1) , 57-60
Abstract
Elevated blood pressure is associated with an increased risk of cardiovascular illness and death. Efforts to reduce that risk have led to recommendations for a wide array of nondrug and drug therapies. Choosing the optimal first-line drug for hypertensive patients should address a hierarchy of treatment goals: decrease in morbidity and mortality associated with hypertension, decrease in blood pressure, lack of effect on patients' quality of life, dosing convenience and low cost. This article examines the evidence for thiazide diuretics as a class of first-line antihypertensive drugs in light of these treatment goals. The evidence indicates that low-dose thiazides are preferable to high-dose thiazides and that low-dose thiazides are better than or equivalent to other antihypertensive drugs for each of the goals of therapy.This publication has 7 references indexed in Scilit:
- Systematic review of antihypertensive therapies: does the evidence assist in choosing a first-line drug?1999
- Randomised, double blind, multicentre comparison of hydrochlorothiazide, atenolol, nitrendipine, and enalapril in antihypertensive treatment: results of the HANE studyBMJ, 1997
- Health Outcomes Associated With Antihypertensive Therapies Used as First-Line AgentsA Systematic Review and Meta-analysisJAMA, 1997
- Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group.1996
- Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies.1996
- Treatment of Mild Hypertension Study. Final results. Treatment of Mild Hypertension Study Research Group.1993
- Single-Drug Therapy for Hypertension in Men -- A Comparison of Six Antihypertensive Agents with PlaceboNew England Journal of Medicine, 1993